ArticleJournal of autism and developmental disorders2025
The Impact of COVID-19 on Autism Diagnosis and Incidence in the Military Health System.
Article in Journal of autism and developmental disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo determine the effect the COVID-19 pandemic had on autism spectrum disorder (ASD) diagnosis in the Military Health System (MHS).
methodsRepeated cross-sectional study utilized MHS Data Repository from JAN2018 to FEB2023. ASD encounters identified by ICD-10 diagnosis codes. Incident ASD encounters and overall visits were evaluated. Study included periods: Pre-COVID (PCo) (1/18 -2/20), COVID-19 Year (CoY) CoY1(3/20 -2/21), CoY2(3/21 -2/22) and CoY3(3/22 -2/23). Incident rates and overall visits were compared across time periods using Poisson regression, adjusting for sex, age group, region, and parent rank. Median age at first diagnosis across time periods were compared using generalized linear modeling.
results2 million dependents ages 1-17 years were eligible for care over the study, with 44,508 incident ASD diagnoses (Table 1). ASD diagnosis incident rate decreased 10% in CoY1 vs. PCo (RR 0.90, 95% CI 0.87-0.93) and increased during CoY2 and CoY3 [RR2 1.21, 95% CI (1.18-1.24), RR3 1.50, 95% CI (1.46-1.54)]. CoY1-CoY3 vs. PCo all had statistically significant increased ASD visit rates (RR1 1.20, RR2 1.44, RR3 1.67). ASD diagnosis median age was 6 years (Table 1).
conclusionThe incidence of ASD and related encounters decreased at the COVID-19 pandemic onset, highlighting the impact COVID-19 had on a delayed process within the MHS. The ASD incidence and encounters following the pandemic onset improved and continued to increase through CoY3. This uptrend suggests adaptation by providers during COVID-19 restrictions to use telehealth for developmental screening and ASD diagnosis.
Indexed as
Identifiers
41171547What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.